Pharmacotherapy of coronary atherosclerosis.

Pharmacotherapy of coronary atherosclerosis.

Item
http://www.wikidata.org/entity/Q37519710
Molecular prediction for atherogenic risks across different cell types of leukocytes.Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo.Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis.Assessment of vulnerable and unstable carotid atherosclerotic plaques on endarterectomy specimens.The complementary role of microCT and histopathology in characterizing the natural history of stented arteries.Poly(ADP-ribose) polymerase 1 (PARP1) in atherosclerosis: from molecular mechanisms to therapeutic implications.(S)-[6]-Gingerol inhibits TGF-β-stimulated biglycan synthesis but not glycosaminoglycan hyperelongation in human vascular smooth muscle cells.
P2860

Pharmacotherapy of coronary atherosclerosis.

Item
http://www.wikidata.org/entity/Q37519710
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacotherapy of coronary atherosclerosis.
@en
Pharmacotherapy of coronary atherosclerosis.
@nl
type
label
Pharmacotherapy of coronary atherosclerosis.
@en
Pharmacotherapy of coronary atherosclerosis.
@nl
prefLabel
Pharmacotherapy of coronary atherosclerosis.
@en
Pharmacotherapy of coronary atherosclerosis.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P356
P1433
P1476
Pharmacotherapy of coronary atherosclerosis.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921